Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.

Martinez, Fernando J; Afzal, Amna Sadaf; Smith, Jaclyn A; Ford, Anthony P; Li, Jerry Jing; Li, Yuping; Kitt, Michael M

Martinez, Fernando J; Afzal, Amna Sadaf; Smith, Jaclyn A; Ford, Anthony P; Li, Jerry Jing; Li, Yuping; Kitt, Michael M.

Afiliação

Martinez FJ; Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York City, NY, USA. fjm2003@med.cornell.edu.
Afzal AS; Merck & Co., Inc., Kenilworth, NJ, USA.
Smith JA; Division of Infection, Immunity and Respiratory Medicine, University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.
Ford AP; Merck & Co., Inc., Kenilworth, NJ, USA.
Li JJ; Merck & Co., Inc., Kenilworth, NJ, USA.
Li Y; GetStat Solutions, LLC, Palo Alto, CA, USA.
Kitt MM; Merck & Co., Inc., Kenilworth, NJ, USA.

Pulm Ther ; 7(2): 471-486, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34152585

Palavras-chave

AF-219; Chronic cough; Gefapixant; Idiopathic pulmonary fibrosis; MK-7264; P2X3 receptor antagonist; Treatment-refractory chronic cough

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: Pulm Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google